{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:42:59Z","timestamp":1775706179299,"version":"3.50.1"},"reference-count":56,"publisher":"European Respiratory Society (ERS)","issue":"167","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2022,12,12]]},"published-print":{"date-parts":[[2023,3,31]]},"abstract":"<jats:p>Pulmonary hypertension (PH) is a prevalent disease of the pulmonary vasculature that is characterised by considerable morbidity and mortality. Substantial efforts have been made in recent years to improve disease recognition, diagnosis and management, and this is reflected in current guidelines. The haemodynamic definition of PH has been revised and a definition for exercise PH has been provided. Risk stratification has been refined and the importance of comorbidities and phenotyping have been highlighted. These changes provide an opportunity to potentially identify pulmonary vascular disease at an earlier stage and to enhance patient-centred, goal-orientated treatment decisions. A promising fourth treatment pathway for pulmonary arterial hypertension and potential targeted therapies for group 3 PH are on the horizon, concepts which seemed inconceivable only a few years ago. Beyond medication, there is a greater appreciation for the importance of supervised training in stable PH and the possible role of interventional therapies in select cases. The landscape of PH is changing and it is characterised by progress, innovation and opportunities. In this article, we highlight some of the new trends in PH, with a specific focus on the revised European Society of Cardiology\/European Respiratory Society 2022 guidelines for the diagnosis and management of PH.<\/jats:p>","DOI":"10.1183\/16000617.0211-2022","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T09:15:18Z","timestamp":1677057318000},"page":"220211","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["New trends in pulmonary hypertension"],"prefix":"10.1183","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4831-2268","authenticated-orcid":false,"given":"Sarah","family":"Cullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Gaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-1951","authenticated-orcid":false,"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"2024102404104615000_32.167.220211.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022"},{"key":"2024102404104615000_32.167.220211.2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30317-9","article-title":"Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study","volume":"8","author":"Maron","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102404104615000_32.167.220211.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00184412"},{"key":"2024102404104615000_32.167.220211.4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.healun.2020.09.011","article-title":"Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry","volume":"39","author":"Hoeper","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"2024102404104615000_32.167.220211.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2015.12.016"},{"key":"2024102404104615000_32.167.220211.6","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1164\/rccm.202206-1041ST","article-title":"Syndrome of combined pulmonary fibrosis and emphysema: an official ATS\/ERS\/JRS\/ALAT research statement","volume":"206","author":"Cottin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404104615000_32.167.220211.7","first-page":"A5302","article-title":"A new clinical phenotype with non-plexiform vasculopathy and distinctive microvessel remodeling among idiopathic pulmonary arterial hypertension patients","volume":"205","author":"Nossent","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404104615000_32.167.220211.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02165-2019"},{"key":"2024102404104615000_32.167.220211.9","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2024102404104615000_32.167.220211.10","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2024102404104615000_32.167.220211.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2014.09.004"},{"key":"2024102404104615000_32.167.220211.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.983866"},{"key":"2024102404104615000_32.167.220211.13","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"2024102404104615000_32.167.220211.14","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/ehf2.13225","article-title":"Acute pulmonary pressure change after transition to sacubitril\/valsartan in patients with heart failure reduced ejection fraction","volume":"8","author":"Tran","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2024102404104615000_32.167.220211.15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13023-017-0626-0","article-title":"Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method","volume":"12","author":"Freitas","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2024102404104615000_32.167.220211.16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032-2015"},{"key":"2024102404104615000_32.167.220211.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470"},{"key":"2024102404104615000_32.167.220211.18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.healun.2022.02.002","article-title":"Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension","volume":"41","author":"Humbert","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"2024102404104615000_32.167.220211.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209657"},{"key":"2024102404104615000_32.167.220211.20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S2213-2600(18)30367-9","article-title":"Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial","volume":"7","author":"Sadushi-Kolici","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102404104615000_32.167.220211.21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S2213-2600(22)00214-4","article-title":"Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study","volume":"10","author":"Ja\u00efs","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102404104615000_32.167.220211.22","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0165-2021"},{"key":"2024102404104615000_32.167.220211.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00465-2017"},{"key":"2024102404104615000_32.167.220211.24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.chest.2021.07.2162","article-title":"Riociguat for sarcoidosis-associated pulmonary hypertension: results of a 1-year double-blind, placebo-controlled trial","volume":"161","author":"Baughman","year":"2022","journal-title":"Chest"},{"key":"2024102404104615000_32.167.220211.25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020"},{"key":"2024102404104615000_32.167.220211.26","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"2024102404104615000_32.167.220211.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01347-2022"},{"key":"2024102404104615000_32.167.220211.28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1164\/rccm.202001-0087ED","article-title":"mTORC1 in pulmonary arterial hypertension. At the crossroads between vasoconstriction and vascular remodeling?","volume":"201","author":"Goncharova","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404104615000_32.167.220211.29","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1164\/rccm.201911-2137OC","article-title":"Loss of DP1 aggravates vascular remodeling in pulmonary arterial hypertension via mTORC1 signaling","volume":"201","author":"He","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404104615000_32.167.220211.30","first-page":"A4409","article-title":"ABI-009, nab-sirolimus, an mTOR inhibitor with high lung accumulation in preclinical models is active in patients with severe pulmonary arterial hypertension","volume":"199","author":"Simon","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404104615000_32.167.220211.31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02356-2021"},{"key":"2024102404104615000_32.167.220211.32","doi-asserted-by":"crossref","first-page":"20458940211057071","DOI":"10.1177\/20458940211057071","article-title":"TORREY, a phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension","volume":"11","author":"Frantz","year":"2021","journal-title":"Pulm Circ"},{"key":"2024102404104615000_32.167.220211.33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"2024102404104615000_32.167.220211.34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00332-2018"},{"key":"2024102404104615000_32.167.220211.35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv337"},{"key":"2024102404104615000_32.167.220211.36","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/eurheartj\/ehaa696","article-title":"Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial","volume":"42","author":"Gr\u00fcnig","year":"2021","journal-title":"Eur Heart J"},{"key":"2024102404104615000_32.167.220211.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045460"},{"key":"2024102404104615000_32.167.220211.38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.94.6.1249"},{"key":"2024102404104615000_32.167.220211.39","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.1.10"},{"key":"2024102404104615000_32.167.220211.40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.112.971077"},{"key":"2024102404104615000_32.167.220211.41","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02409-2016"},{"key":"2024102404104615000_32.167.220211.42","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02095-2018"},{"key":"2024102404104615000_32.167.220211.43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-2600(22)00171-0","article-title":"Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial","volume":"10","author":"Kawakami","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102404104615000_32.167.220211.44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00270-020-02714-z","article-title":"Evaluation of outcomes following pulmonary artery stenting in fibrosing mediastinitis","volume":"44","author":"Welby","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2024102404104615000_32.167.220211.45","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-007-9009-6"},{"key":"2024102404104615000_32.167.220211.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.01.025"},{"key":"2024102404104615000_32.167.220211.47","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(83)90678-1"},{"key":"2024102404104615000_32.167.220211.48","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.hlc.2013.01.005","article-title":"Percutaneous atrial septostomy with modified butterfly stent and intracardiac echocardiographic guidance in a patient with syncope and refractory pulmonary arterial hypertension","volume":"22","author":"Roy","year":"2013","journal-title":"Heart Lung Circ"},{"key":"2024102404104615000_32.167.220211.49","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00072210"},{"key":"2024102404104615000_32.167.220211.50","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.9.797"},{"key":"2024102404104615000_32.167.220211.51","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04633-2020"},{"key":"2024102404104615000_32.167.220211.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.075"},{"key":"2024102404104615000_32.167.220211.53","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1186\/s12864-016-3122-3","article-title":"Multi-omics analysis reveals regulators of the response to PDGF-BB treatment in pulmonary artery smooth muscle cells","volume":"17","author":"Chen","year":"2016","journal-title":"BMC Genomics"},{"key":"2024102404104615000_32.167.220211.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2019.12.027"},{"key":"2024102404104615000_32.167.220211.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2018.09.021"},{"key":"2024102404104615000_32.167.220211.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.06.064"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0211-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:05:41Z","timestamp":1740373541000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0211-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":56,"journal-issue":{"issue":"167","published-online":{"date-parts":[[2023,2,21]]},"published-print":{"date-parts":[[2023,3,31]]}},"alternative-id":["10.1183\/16000617.0211-2022"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0211-2022","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]}}}